Award
National Cancer Institute 1R21CA292338-01
Tumor-Activated Dual Payload-Drug Conjugates
Recipient
National Cancer Institute (NCI), part of the NIH
Award Amount
$393,401.00
Ceiling
$393,401.00
Awarded
July 01, 2024
Identifier
1R21CA292338-01
Award for developing PSMA-targeted dual drug conjugates to treat prostate cancer, addressing tumor heterogeneity and drug resistance.
Description
This project involves developing PSMA-targeted small-molecule dual drug conjugates for prostate cancer treatment, with a focus on tumor heterogeneity and drug resistance. The project is funded by NIH/NCI under grant PAR-22-216.